In a challenging market environment, Halyard Health , Inc. (NYSE: NYSE:AVNS) stock has reached a 52-week low, dipping to $14.24. The healthcare company, known for its medical supplies and solutions, has faced significant headwinds over the past year, reflected in a substantial 1-year decline of -27.11%. According to InvestingPro analysis, the stock appears undervalued, with technical indicators suggesting oversold conditions. The company maintains a solid gross margin of 55.44% and generates annual revenue of $687.8M. Investors are closely monitoring the company’s performance as it navigates through the pressures of the healthcare sector, which have been exacerbated by economic uncertainties and competitive dynamics. The current price level marks a critical point for AVNS as market participants consider the stock’s valuation and future prospects. InvestingPro data reveals encouraging signs, with analysts expecting net income growth this year. Discover 8 more exclusive ProTips and comprehensive valuation metrics with an InvestingPro subscription, including the detailed Pro Research Report available for AVNS and 1,400+ other US stocks.
In other recent news, Avanos Medical reported better-than-expected financial results for the fourth quarter of 2024. The company announced earnings per share of $0.43, surpassing the anticipated $0.40, and revenue of $179.6 million, exceeding the forecasted $177.23 million. Additionally, Avanos completed the sale of its Respiratory Health business, which is part of its ongoing transformation strategy. The company also appointed David Pacitti as the new CEO, effective April 2025, bringing extensive experience from his previous role at Siemens (ETR:SIEGn) Medical (TASE:BLWV) Solutions USA. Avanos Medical has set a net sales guidance for 2025 between $665 million and $685 million, with an adjusted EPS guidance of $1.05 to $1.25. The company aims for long-term gross margins of over 60% and EBITDA margins of 20%. In the meantime, Avanos continues to focus on organic growth, particularly in its Specialty Nutrition Systems segment. The company also received an upgrade in its strategic outlook from certain analyst firms, reflecting confidence in its transformation initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.